Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approa...

Por Choueiri, Toni K., Cheng, Suchun, Qu, Angela Q., Pastorek, Jaromir, Atkins, Michael B., Signoretti, Sabina
Publicado no Urol Oncol (2012)

Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting

Por Euesden, Jack, Gowrisankar, Sivakumar, Qu, Angela Xiaoyan, St. Jean, Pamela, Hughes, Arlene R., Pulford, David J.
Publicado no Genes (Basel) (2020)

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker...

Por Choueiri, Toni K., Jacobus, Susanna, Bellmunt, Joaquim, Qu, Angela, Appleman, Leonard J., Tretter, Christopher, Bubley, Glenn J., Stack, Edward C., Signoretti, Sabina, Walsh, Meghara, Steele, Graeme, Hirsch, Michelle, Sweeney, Christopher J., Taplin, Mary-Ellen, Kibel, Adam S., Krajewski, Katherine M., Kantoff, Philip W., Ross, Robert W., Rosenberg, Jonathan E.
Publicado no J Clin Oncol (2014)

Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma

Por Agarwal, Neeraj, Bellmunt, Joaquim, Maughan, Benjamin L., Boucher, Kenneth M., Choueiri, Toni K., Qu, Angela Q., Vogelzang, Nicholas J., Fougeray, Ronan, Niegisch, Guenter, Albers, Peter, Wong, Yu-Ning, Ko, Yoo-Joung, Sridhar, Srikala S., Tantravahi, Srinivas K., Galsky, Matthew D., Petrylak, Daniel P., Vaishampayan, Ulka N., Mehta, Amitkumar N., Beer, Tomasz M., Sternberg, Cora. N., Rosenberg, Jonathan E., Sonpavde, Guru
Publicado em 2013

Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2...

Por Sonpavde, Guru, Pond, Gregory R., Fougeray, Ronan, Choueiri, Toni K., Qu, Angela Q., Vaughn, David J., Niegisch, Guenter, Albers, Peter, James, Nicholas D., Wong, Yu-Ning, Ko, Yoo-Joung, Sridhar, Srikala S., Galsky, Matthew D., Petrylak, Daniel P., Vaishampayan, Ulka N., Khan, Awais, Vogelzang, Nicholas J., Beer, Tomasz M., Stadler, Walter M., O’Donnell, Peter H., Sternberg, Cora N., Rosenberg, Jonathan E., Bellmunt, Joaquim
Publicado em 2012

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Por Van Allen, Eliezer M., Mouw, Kent W., Kim, Philip, Iyer, Gopa, Wagle, Nikhil, Al-Ahmadie, Hikmat, Zhu, Cong, Ostrovnaya, Irina, Kryukov, Gregory V., O’Connor, Kevin W, Sfakianos, John, Garcia-Grossman, Ilana, Kim, Jaegil, Guancial, Elizabeth A., Bambury, Richard, Bahl, Samira, Gupta, Namrata, Farlow, Deborah, Qu, Angela, Signoretti, Sabina, Barletta, Justine A., Reuter, Victor, Boehm, Jesse, Lawrence, Michael, Getz, Gad, Kantoff, Philip, Bochner, Bernard H., Choueiri, Toni K., Bajorin, Dean F., Solit, David B., Gabriel, Stacey, D’Andrea, Alan, Garraway, Levi A., Rosenberg, Jonathan E.
Publicado no Cancer Discov (2014)